Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davis Ballard

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Molecular Pharmaceutics|September 3, 2024
Bismuth-Cyclized Cell-Penetrating PeptidesJeremy L Ritchey, Lindsi Filippi, Davis Ballard, et al.
Frontiers in Oncology|October 3, 2025
Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancerZhuoxin Zora Zhou, Davis Ballard, Tanvi Varadkar, et al.
Cancer Research Communications|April 21, 2026
Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer TherapyZhuoxin Zhou, Davis Ballard, Jiashuai Zhang, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Molecular Pharmaceutics|September 3, 2024
Bismuth-Cyclized Cell-Penetrating PeptidesJeremy L Ritchey, Lindsi Filippi, Davis Ballard, et al.
Frontiers in Oncology|October 3, 2025
Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancerZhuoxin Zora Zhou, Davis Ballard, Tanvi Varadkar, et al.
Cancer Research Communications|April 21, 2026
Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer TherapyZhuoxin Zhou, Davis Ballard, Jiashuai Zhang, et al.
Pageof 1